from TetraKit Technologies
March 18, 2024
We are thrilled to announce our participation in the upcoming 7th Theranostics World Congress, where our esteemed experts will be sharing groundbreaking insights and innovations in the field of theranostics.
Dr. Andreas Jensen, CEO and co-founder of TetraKit Technologies, will be giving a talk on March 24th, highlighting our platform’s inventive application in next-generation theranostics.
Dr. Matthias Herth, our CSO, will take the stage on March 23rd to discuss ²¹¹At-PSMA for alpha-RLT (Radioligand Therapy) of prostate cancer, showcasing TetraKit’s advancements in personalized cancer treatment.
Dr. Marcel Martin, our Senior Radiochemistry expert, will present on March 24th, focusing on new dimeric FAPi radioligands and their optimized properties for radioligand therapy to improve therapeutic efficacy.
Join us at our booth during the conference for engaging discussions, valuable insights, and a closer look at our latest innovations. Your presence will add immense value to these special occasions as we collectively explore the future of theranostics and healthcare innovation.
Don’t miss this opportunity to connect, learn, and collaborate! Visit the 7th Theranostics World Congress website and join our presentations. See you there! 🚀 #TetraKitTechnologies #TheranosticsWorldCongress #HealthcareInnovation
Read more
October 11, 2023
The 4th Working Group and Core Group meeting of the COST Action CA19114 / COST NOAR Astatine – Network for Optimized Astatine-labeled Radiopharmaceuticals is currently underway. The meeting is being held at the Faculty of Pharmacy, University of Ljubljana in Slovenia, from October 9th to 11th, 2023. Stay tuned for updates on the latest developments in the field of optimized astatine-labeled radiopharmaceuticals.
Read more
September 12, 2023
Today at #EANM23 in Vienna, Dr. Umberto Battisti presented our data and findings as an EANM-highlighted lecture. We are grateful for the opportunity to show our data to the scientific community dedicated to this field.
Please reach out if you want to hear more about our platform technology.
#Radiotheranostics #TetraKitTechnologies
Chief Executive Officer
“Targeted radionuclide therapy has been demonstrated to be very effective in oncology. However, a practical and universal labeling platform has thus far not been developed. TetraKit Technologies will develop such a platform. We expect that this platform will bring more powerful treatments to patients, especially with advanced metastatic cancer.”
Chief Scientific Officer
“TetraKit Technologies does not only provide a new platform enabling kit-labeling of almost any targeting vector with any radionuclide, but will also apply this technology to develop NextGen Theranostics based on the theranostic radionuclide pair fluoride-18 and astatine-211.”
© 2022 TetraKit Technologies. All rights reserved
Privacy Policy
